Allon Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported net loss of $2,778,704 or $0.03 per share compared to a net loss of $2,974,076 or $0.04 per share for the three months ended March 31, 2011, representing a decrease in net loss of $195,372. The company earned interest revenue of $43 during the three months ended March 31, 2012 compared to $4,900 for the same period in 2011.